AbbVie is a drugmaker built around immunology, with Humira's long decline giving way to Skyrizi and Rinvoq, plus oncology, neuroscience and a large aesthetics arm led by Botox.
The stock trades on whether Skyrizi and Rinvoq can grow fast enough to replace lost Humira sales, and on how the company handles its heavy dividend and pipeline spending.